Back

Development of Q-LAAD, an allonamer-based antigen test for the rapid detection of SARS-CoV-2

Overgaard, E.; Li, S.; Covert, H. J.; Tawara, K.; Poe, A. M.; Shults, N. H.; Chernish, A. A.; Sweet, B.; Gonzales, C. R.; Gibard, C. F.; Burden, S. J.

2022-09-25 infectious diseases
10.1101/2022.09.23.22280297
Show abstract

The SARS-CoV-2 virus has spread globally causing coronavirus disease 2019 (COVID-19). Rapidly and accurately identifying viral infections is an ongoing necessity. We used the systematic evolution of ligands by exponential enrichment (SELEX) technique to produce a DNA allonamer with two distinct binding domains made allosteric through a linker section; one domain binds SARS-CoV-2 spike (S) protein, inducing a conformational change that allows the reporter domain to bind a fluorescent reporter molecule. We used bead-based fluorescence and immunofluorescence assays to confirm the allonamers affinity and specificity for S-protein and confirmed that the allonamer can bind to S-proteins with mutations corresponding to those of the alpha, beta, gamma, and delta variants. We then developed the allonamer-based Quantum-Logic Aptamer Analyte Detection (Q-LAAD) test, a rapid, high-throughput antigen test for qualitative detection of SARS-CoV-2 in clinical settings. We validated Q-LAAD against retrospective and prospective clinical anterior nasal swab samples collected from symptomatic patients suspected of having COVID-19. Q-LAAD showed 97% sensitivity and 100% specificity compared to the RT-qPCR assay. Q-LAAD has a limit of detection (LOD) of 1.88 TCID50/mL, is cost-effective and convenient, and requires only a common fluorescence plate reader. Q-LAAD may be a useful clinical diagnostic tool in the fight against SARS-CoV-2. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=200 SRC="FIGDIR/small/22280297v1_ufig1.gif" ALT="Figure 1"> View larger version (86K): org.highwire.dtl.DTLVardef@1250f56org.highwire.dtl.DTLVardef@11eb2dorg.highwire.dtl.DTLVardef@6711dcorg.highwire.dtl.DTLVardef@c5bf3e_HPS_FORMAT_FIGEXP M_FIG C_FIG HIGHLIGHTSO_LIAllonamers are allosterically-regulated DNA aptamers with multiple binding pockets C_LIO_LIQ-LAAD uses allonamers to detect SARS-CoV-2 spike protein in clinical samples C_LIO_LIQ-LAAD has high sensitivity and specificity and a low limit of detection C_LIO_LIQ-LAAD can detect spike proteins from multiple SARS-CoV-2 variants C_LIO_LIQ-LAAD is a dynamic, cost-effective rapid antigen test for detection of SARS-CoV-2 C_LI

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

1
Biosensors and Bioelectronics
based on 13 papers
Top 0.1%
15.6%
2
Scientific Reports
based on 701 papers
Top 22%
7.7%
3
Analytical Chemistry
based on 15 papers
Top 0.1%
6.5%
4
Cell Reports Medicine
based on 49 papers
Top 0.3%
5.9%
5
PLOS ONE
based on 1737 papers
Top 72%
4.6%
6
Nature Communications
based on 483 papers
Top 17%
4.6%
7
Journal of Clinical Microbiology
based on 77 papers
Top 2%
2.8%
8
The Journal of Molecular Diagnostics
based on 24 papers
Top 0.7%
2.3%
9
Journal of Virological Methods
based on 20 papers
Top 0.9%
2.3%
50% of probability mass above
10
Viruses
based on 79 papers
Top 2%
2.3%
11
Clinical Chemistry
based on 14 papers
Top 0.5%
1.9%
12
Med
based on 26 papers
Top 0.2%
1.6%
13
iScience
based on 74 papers
Top 3%
1.6%
14
eBioMedicine
based on 82 papers
Top 2%
1.6%
15
Frontiers in Medicine
based on 99 papers
Top 13%
1.3%
16
Science Translational Medicine
based on 40 papers
Top 3%
1.3%
17
Nature
based on 58 papers
Top 6%
1.3%
18
eLife
based on 262 papers
Top 29%
0.8%
19
The Journal of Immunology
based on 19 papers
Top 2%
0.8%
20
EMBO Molecular Medicine
based on 15 papers
Top 2%
0.8%
21
Communications Medicine
based on 63 papers
Top 3%
0.8%
22
mBio
based on 34 papers
Top 3%
0.8%
23
Life Science Alliance
based on 11 papers
Top 0.3%
0.8%
24
Journal of Clinical Virology
based on 54 papers
Top 4%
0.7%
25
Microbiology Spectrum
based on 86 papers
Top 3%
0.7%
26
EBioMedicine
based on 21 papers
Top 2%
0.7%
27
Nature Medicine
based on 88 papers
Top 19%
0.7%